
    
      This is a Phase II clinical study to collect additional safety data and preliminary
      efficiency of juvenile chondrocytes, delivered in fibrin carrier (NuQuÂ®) to the nucleus of
      lumbar intervertebral discs for the treatment of discogenic pain. This to be accomplished
      through a double blinded, placebo-controlled study of clinically meaningful endpoints
      including validated, subject reported outcomes of pain and disability, health related quality
      of life and subject satisfaction with treatment.
    
  